In contrast to chromosome 1p/19q codeletion requiring fluorescence in-situ hybridization (FISH)analysis and MGMT promoter methylation requiring methylation-specific PCR (MSP), which are important diagnostic and predictive markers of glioma, IDH1 status could be readily evaluated by anti-IDH1-R132H immunohistochemistry for the most common mutant or by PCR followed by direct sequencing for all the mutant of the two mutation hotspots of IDH1 and IDH2.Our study examined the IDH1/IDH2 status of 53 pairs of primary and recurrent gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.